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Dear Editor,
FK506-binding protein (FKBP) 51 is a cochaperone, which
belongs to the immunophilin family, a group of proteins with
peptidyl-prolyl isomerase activity. FKBPs regulate several
biological processes through protein–protein interaction.
1 In
particular, FKBP51 is a component of the steroid receptor
complex, with a role in steroid resistance;
2 moreover, it is
involved in NF-kB activation because of its isomerase activity,
whichisessentialforthefunctionofsubunit-aintheIkBkinase
complex.
3 According to Baughman et al.,
4 FKBP51 is
abundantly expressed in lymphocytes and in several other
tissues, but it is expressed at low levels in the pancreas,
spleen, and stomach. There is increasing evidence of an
association of FKBP51 hyperexpression with cancer
6–8 and a
relevant role of this protein in sustaining cell growth,
5
malignancy, and resistance to therapy.
6–8 An immunohisto-
chemistry study of expression of FKBP51 in 50 tumoral
samples acquired from our pathology section, including
breast, lung, pancreas, ovary, and prostate (10 samples for
each tumor), and a comparable number of normal tissue
samples showed an intense signal in 38 out of 50 tumors
analyzed, whereas normal tissues of the same histotypes
showed a weak/absent immunohistochemical signal. The 12
tumor samples with low/negative immunohistochemistry were
the 10 breast cancer samples and 2 out of 10 pancreatic
tumors. Interestingly, these two pancreatic tumors belonged
to the well-differentiated histotype (G1). Figure 1a (upper
panel) shows representative immunohistochemical ﬁndings.
Measurement of FKBP51 mRNA levels in deparafﬁnized
tissues using real-time PCR conﬁrmed the immunohisto-
chemistry results (representative results in Figure 1a, lower
panel). Taken together, these ﬁndings support the hypothesis
that FKBP51 is a promising novel tumoral marker. The
association of FKBP51 overexpression with cancer is in line
with the rapidly emerging concept that NF-kB drives tumor-
igenesis in the most common genetic alterations associated
with cancer.
9,10
Recently,ithasbeenfound,intumorcelllines,thatFKBP51
actedasascaffoldtofacilitatetheinteractionbetweenAktand
PH domain leucine-rich repeat protein phosphatase, which
mediates dephosphorylation of pAkt (S473).
11 This raised the
question whether FKBP51 may work out as a tumor
suppressor by deactivating Akt. As we previously found that
intratumoralinjectionofFKBP51siRNAfollowedbyirradiation
produced extensive apoptosis in melanoma xenografts,
8 we
investigated the effect of FKBP51 downmodulation on pAkt
(S473) levels in our mouse model of melanoma, in both
xenografts and locoregional lymph nodes. Histological
examination showed that the mouse lymphatic tissue was
not metastatic. Figure 1b shows a representative outcome.
On the basis of these results, pAkt (S473) levels were not
enhanced with downmodulation of FKBP51 in normal or
cancerous tissue.
This observation suggests that pathways upstream from
Akt, which are often deregulated in cancer, control activated-
Akt levels. This hypothesis is supported by the ﬁndings
that leukemic lymphocytes often display higher levels of
pAkt (S473) in comparison with normal lymphocytes
(Figure 1c) even in the presence of similar or higher FKBP51
levels. To assess whether an inverse correlation subsisted
between FKBP51 and pAkt (S473) levels, we used
western blot to measure these levels in samples of primary
lymphatic leukemia and normal peripheral blood lympho-
cytes. Expression levels were quantiﬁed by densitometry.
Spearman’s r correlation did not indicate any relationship
between the two variables (Figure 1d; P¼0.788, left;
P¼0.199, right). Taken together, these ﬁndings do not
support an essential role of FKBP51 as a factor that controls
the phosphorylation status of Akt inside the cell, thereby
weakening the hypothesis that the protein may work out as
tumor suppressor.
In conclusion, although FKBP51 function is not yet fully
elucidated, however, there are clear data suggesting that this
immunophilin is often hyperexpressed in tumors and has an
active role in pre-neoplastic disorders
5 and cancer.
6–8
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Figure 1 (a) (Upper panel) FKBP51 immunochemical staining of normal and neoplastic tissues. Serial sections of 4mm from routinely formalin-ﬁxed, parafﬁn-embedded
blockswere cut and mounted on poly-L-lysine-coated glass slides. (Lower panel) Deparafﬁnized sections were incubated overnight at 41C with anti-FKBP51 primary antibody
(F-13,SantaCruzBiotechnology,SantaCruz,CA,USA)diluted1:50.Thestandardstreptavidin–biotin–peroxidasecomplextechniquewasperformed.Hematoxylinwasused
fornuclearcounterstaining.(Lowerpanel)NormalizedexpressionratesofFKBP51mRNA(a.u.,arbitraryunits)inPBLanddeparafﬁnizedtissues;eachhistogramisreferredto
a representative normal or tumoral sample. Values represent means and S.D. of arbitrary units from three different real-time experiments, each performed in triplicate. Total
RNA was isolated from PBLs with Trizol (Invitrogen, Carlsbad, CA, USA) and from parafﬁnized tumors using the High Pure RNA Parafﬁn Kit (Roche Diagnostics GmbH,
Mannheim, Germany) according to the manufacturer’s instructions. In all, 1mg of each RNA was used for cDNA synthesis with Moloney Murine Leukemia Virus Reverse
Transcriptase (M-MLV RT, Invitrogen). Gene expression was quantiﬁed by real-time PCR using the iQ SYBR Green Supermix (Bio-Rad, Foster City, CA, USA) and speciﬁc
real-time-validated QuantiTect primers for FKBP51 (FW: 50-GTGGGGAATGGTGAGGAAACGC-30; REV: 50-CATGGTAGCCACCCCAATGTCC-30) and speciﬁc primers for
b-actin.RelativequantitationofFKBP51transcriptacrossmultiplesampleswasperformedbyusingacoampliﬁedb-actininternalcontrolforsamplenormalization.Thevalues
ofeachsamplewerecomparedto PBL(expression¼1)foranestimateoftherelativeexpressionchangefoldofFKBP51.(b)WesternblotassayofpAkt(S473)andFKBP51
levels in lysates preparedfrom melanomaxenografts and locoregional lymph nodes obtained from athymic nu/nu mice (Charles River Laboratory, Wilmington,MA, USA). For
pAkt(S473)detection,therabbitpolyclonalantibodycloneD9E(CellSignaling,Danvers,MA,USA)wasused,andforFKBP51,thegoatpolyclonalantibodyF-13(SantaCruz
Biotechnology)wasused.WhentumorsreachedB10mminmeandiameter,micereceivedasingleintratumoralinjectionofFKBP51siRNA(50-ACCUAAUGCUGAGCUdAU-30)
or (nonsilencing) NS RNA. After 48h, mice were subjected to tumor irradiation, and after a further 48h, animals were killed and tumors and lymph nodes excised for
preparationoflysates.(c) Westernblot assaysof pAkt(S473) andFKBP51levels inlysatespreparedfromdifferentsamplesof mononuclearcells.Mononuclear cellsof acute
lymphoblastic leukemia (ALL) were separated by bone marrow; BMMCs were bone marrow mononuclear cells separated from a noninﬁltrated bone marrow sample from a
lymphoma patient. Mononuclear cells of chronic lymphocytic leukemia (CLL) were separated by peripheral blood. Peripheral blood lymphocytes (PBLs) were from normal
donors. (d) Scatterplot of FKBP51 OD versus pAkt (S473) OD. FKBP51 and pAkt (S473) expression levels were quantiﬁed by densitometry using ImageJ 1.42q (NIH, http://
rsb.info.nih.gov/ij/) for Macintosh. Integrated ODs of pAkt were normalized to Akt, whereas integrated ODs of FKBP51 were normalized to actin
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